DOGMA THERAPEUTICS

The pharmaceutical industry has struggled to identify small molecule inhibitors of PCSK9 function. This has been explained by the expansive but flat binding interface between PCSK9 and the LDL receptor, spanning nearly 800 square angstroms. To date, only monoclonal antibodies have been able to target this region of PCSK9. We have discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species. Guided by dozens of high-resolution x-ray structures of our molecules bound to PCSK9, we have utilized structure-based design to achieve picomolar affinity.

#People #Financial #Website #More

DOGMA THERAPEUTICS

Industry:

Biotechnology Pharmaceutical

Founded:

2017-01-01

Address:

Boxford, Massachusetts, United States

Country:

United States

Website Url:

http://www.dogmatherapeutics.com

Total Employee:

1+

Status:

Active

Email Addresses:

[email protected]

Total Funding:

3.5 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Google Apps For Business Google GStatic Google Static Content Google Cloud

Current Employees Featured

doug-daniels_image

Doug Daniels
Doug Daniels Founder @ Dogma Therapeutics
Founder

Founder

doug-daniels_image

Doug Daniels

Investors List

jmcr-partners_image

JMCR Partners

JMCR Partners investment in Series A - Dogma Therapeutics

viva-biotech_image

Viva BioInnovator

Viva BioInnovator investment in Series A - Dogma Therapeutics

viva-ventures-biotech-group_image

Viva Ventures Biotech Fund

Viva Ventures Biotech Fund investment in Series A - Dogma Therapeutics

Official Site Inspections

http://www.dogmatherapeutics.com

Host Informations
Whois Informations

Loading ...

More informations about "Dogma Therapeutics" on Search Engine